Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HQP1351 in Patients With GIST or Other Solid Tumors
NCT03594422Phase 1Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Jul 2018
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olverembatinib in gastrointestinal stromal tumor (GIST) and solid tumor (4 arms), sponsored by Ascentage Pharma. Primary endpoint: Safety and tolerance. Started Jul 2018; status: recruiting.
02
Drugs
olverembatinib
03
Conditions
gastrointestinal stromal tumor (GIST)solid tumor
Beyond the preview
Go deeper on NCT03594422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03594422.